drugset / Trial / NCT01862263
Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to assess if the addition of vildagliptin as add-on therapy improves glucose variability in type 2 diabetes mellitus (T2DM) patients inadequately controlled with insulin, with special emphasis in hypoglycemic episodes measured by continuous glucose monitoring.
Timeline
- Start
- 2013-05
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vildagliptin | Other / unclassified | 50 mg | Oral |
| Background | Insulin | Protein / enzyme biologic | 20 iu | — |
| Background | Insulin | Protein / enzyme biologic | 40 iu | — |